Last reviewed · How we verify
Glucobay®
At a glance
| Generic name | Glucobay® |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313) (PHASE4)
- Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes (PHASE4)
- GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients
- GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucobay® CI brief — competitive landscape report
- Glucobay® updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI